CN115443136A - 使用btk抑制剂对急性呼吸窘迫综合征和涉及细胞因子风暴的其他障碍的治疗 - Google Patents

使用btk抑制剂对急性呼吸窘迫综合征和涉及细胞因子风暴的其他障碍的治疗 Download PDF

Info

Publication number
CN115443136A
CN115443136A CN202180029932.7A CN202180029932A CN115443136A CN 115443136 A CN115443136 A CN 115443136A CN 202180029932 A CN202180029932 A CN 202180029932A CN 115443136 A CN115443136 A CN 115443136A
Authority
CN
China
Prior art keywords
carbonyl
amino
pyrazolo
pyrimidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180029932.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·朗格里什
D·托马斯
S·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Principia Biopharma Inc
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of CN115443136A publication Critical patent/CN115443136A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180029932.7A 2020-04-22 2021-04-21 使用btk抑制剂对急性呼吸窘迫综合征和涉及细胞因子风暴的其他障碍的治疗 Pending CN115443136A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
US63/013,784 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Publications (1)

Publication Number Publication Date
CN115443136A true CN115443136A (zh) 2022-12-06

Family

ID=75919390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029932.7A Pending CN115443136A (zh) 2020-04-22 2021-04-21 使用btk抑制剂对急性呼吸窘迫综合征和涉及细胞因子风暴的其他障碍的治疗

Country Status (12)

Country Link
US (1) US20230158031A1 (enExample)
EP (1) EP4138836A1 (enExample)
JP (2) JP2023522693A (enExample)
KR (1) KR20230015346A (enExample)
CN (1) CN115443136A (enExample)
AU (1) AU2021261327A1 (enExample)
BR (1) BR112022020974A2 (enExample)
CA (1) CA3175788A1 (enExample)
IL (1) IL297316A (enExample)
MX (1) MX2022013164A (enExample)
TW (1) TW202206076A (enExample)
WO (1) WO2021216696A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617259A (zh) * 2025-06-05 2025-09-12 南昌大学第一附属医院 Btk protac化合物nx-5948的新应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
EP2773639B1 (en) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2021211782A1 (en) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Methods of treating acute lung injury and acute respiratory distress syndrome

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617259A (zh) * 2025-06-05 2025-09-12 南昌大学第一附属医院 Btk protac化合物nx-5948的新应用
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Also Published As

Publication number Publication date
BR112022020974A2 (pt) 2022-12-06
AU2021261327A1 (en) 2022-12-22
WO2021216696A1 (en) 2021-10-28
TW202206076A (zh) 2022-02-16
JP2026027386A (ja) 2026-02-18
KR20230015346A (ko) 2023-01-31
IL297316A (en) 2022-12-01
JP2023522693A (ja) 2023-05-31
CA3175788A1 (en) 2021-10-28
MX2022013164A (es) 2022-11-30
US20230158031A1 (en) 2023-05-25
EP4138836A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
JP6838085B2 (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
AU2022228084B2 (en) CRYSTALLINE FORMS OF C21H22Cl2N4O2
AU2014254057A1 (en) Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
AU2014254052A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
JP7701758B2 (ja) 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2026027386A (ja) Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置
JP2025134877A (ja) ＢＴＫ阻害剤２－［（３Ｒ）－３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを使用する、膜性腎症、ＩＧＧ４関連疾患、及び抗リン脂質症候群の処置
US20220380476A1 (en) Use of an anti-CCR7 antibody in combination therapies with a BTK inhibitor and/or BCL2- inhibitor for treating hematological malignancies
HK40101405A (zh) C21H22Cl2N4O2的晶型
EA049231B1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА ПРОТИВ CCR7 В КОМБИНИРОВАННОЙ ТЕРАПИИ С ИНГИБИТОРОМ BTK И/ИЛИ ИНГИБИТОРОМ Bcl-2 ПРИ ЛЕЧЕНИИ ГЕМАТОЛОГИЧЕСКИХ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
WO2026082187A1 (zh) 预防、缓解或治疗癌症的双靶点药物或药物组合物，治疗方法和用途
CN118265527A (zh) 用于治疗纤维化的中性粒细胞弹性蛋白酶抑制剂
HK40129149A (zh) 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的无定形固体分散体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination